Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 11/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1747409 | 0.94 | PRCP (0.69) | PRCPKCNH2CYP3A4CYP2C9NR1I2 | |
| SCHEMBL13748645 | 0.90 | PRCP (0.68) | PRCPKCNH2CYP3A4CYP2C9NR1I2 | |
| SCHEMBL12565050 | 0.88 | PRCP (0.63) | PRCPKCNH2CYP3A4CYP2C9CYP1A2 | |
| SCHEMBL563468 | 0.88 | PRCP (0.54) | PRCPKCNH2HCRTR1HCRTR2 | |
| SCHEMBL563467 | 0.88 | PRCP (0.54) | PRCPKCNH2HCRTR1HCRTR2 | |
| SCHEMBL13747759 | 0.87 | PRCP (0.69) | PRCPKCNH2CYP3A4CYP2C9NR1I2 | |
| SCHEMBL12160080 | 0.86 | PRCP (0.60) | PRCPKCNH2CYP3A4CYP2C9NR1I2 | |
| SCHEMBL13747964 | 0.86 | PRCP (0.61) | PRCPKCNH2CYP3A4CYP2C9NR1I2 | |
| SCHEMBL13747250 | 0.86 | PRCP (0.60) | PRCPKCNH2CYP3A4CYP2C9NR1I2 | |
| SCHEMBL13748256 | 0.85 | PRCP (0.59) | PRCPKCNH2CYP3A4CYP2C9NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436036-B2 | Diaryl ethers | JANSSEN R&D IRELAND (IE) | 2013-05-07 | — | — | US | disclosed |
| US-20120034678-A1 | Diaryl Ethers | JANSSEN SCIENCES IRELAND UC (IE) | 2012-02-09 | — | — | US | disclosed |
| US-20120034678-A1 | Diaryl Ethers | JANSSEN SCIENCES IRELAND UC (IE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034678-A1 | Diaryl Ethers | SLC10A1, CYP2F1, UGT1A1 | PRCP 1514/4885KCNH2 3689/4885CYP3A4 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.